The trial of an Oxford coronavirus vaccine tipped to be the frontrunner in the fight against the pandemic could resume within days after it was halted.
AstraZeneca Plc - which is working alongside the University of Oxford - has confirmed it had had to pause development of the vaccine "to allow review of safety data".
It is believed a British volunteer suffered an adverse reaction during the trial. Health industry website Stat, who first reported the vaccine pause, said the woman was on course to be discharged from hospital as early as last night.
It was described as a "temporary pause" by Pascal Soriot, the chief executive of Astrazeneca. An AstraZeneca spokesperson described the pause as a "routine action" which must happen whenever a